Theoretical potential benefits (currently unproven for rheumatoid arthritis and not studied at microdose levels): Possible anti-inflammatory effects through modulation of immune pathways Weight reduction, which may indirectly benefit joint symptoms in overweight patients Cardiovascular risk reduction, relevant given increased cardiovascular disease risk in rheumatoid arthritis (established in type 2 diabetes populations at therapeutic doses only) [28] Improved metabolic parameters in patients with concurrent metabolic syndrome Known adverse effects of GLP-1 receptor agonists at standard doses include: Gastrointestinal symptoms : nausea, vomiting, diarrhoea, constipation, and abdominal discomfort (very common, affecting more than 1 in 10 patients) Hypoglycaemia : particularly when used with other glucose-lowering medications Injection site reactions : erythema, pruritus, or nodules Pancreatitis : rare but serious, requiring immediate medical attention if severe abdominal pain develops Gallbladder disease : increased risk of cholelithiasis and cholecystitis Thyroid effects : thyroid C-cell tumours observed in rodents
BDH1 iKO-KD, n = 8 mice
It has been associated with alterations in thyroid hormone levels in some studies, which could be relevant for individuals with thyroid disorders or those taking thyroid replacement therapy
In zinc-treated hemodialysis patients, granulocytes exhibit enhanced responsiveness to stimuli like zymosan-activated serum, showing greater chemokinetic activity and motility [139]
Lifestyle and diet play a critical role in how we live and how we age, said Dr
It is noteworthy that a behavioral analysis of Glp1r +/+ , Glp1r +/ and Glp1r/ mouse phenotypes and hippocampal Glp1r gene transfer demonstrated that deficiency of this receptor results in decrements in the acquisition of associative contextual learning which can be improved by hippocampal Glp1r somatic cell gene transfer [45]
